CSIMarket
 


Frequency Therapeutics Inc   (FREQ)
Other Ticker:  
 

Frequency Therapeutics Inc 's Quick Ratio

FREQ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 5.1 below Frequency Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 193 other companies have achieved higher Quick Ratio than Frequency Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 559 to 578.

Explain Quick Ratio?
How much Cash & cash equivalents FREQ´s has?
What are FREQ´s Current Liabilities?


FREQ Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -59.08 % -50.31 % 81.05 % 83.97 % 90.78 %
Y / Y Cash & cash equivalent Change -58 % -58.13 % -43.21 % -36.42 % -32.91 %
Quick Ratio MRQ 5.1 5.58 3.02 3.95 4.97
FREQ's Total Ranking # 578 # 559 # 1019 # 655 # 813
Seq. Current Liabilities Change -1.72 % -62.21 % 4.81 % 5.11 % 19.34 %
Seq. Cash & cash equivalent Change -10.23 % -30.27 % -19.79 % -16.36 % -10.51 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 194
Healthcare Sector # 322
Overall Market # 578


Quick Ratio Statistics
High Average Low
18.7 7.32 2.29
(Jun 30 2021)   (Sep 30 2019)




Financial Statements
Frequency Therapeutics Inc 's Current Liabilities $ 8 Millions Visit FREQ's Balance sheet
Frequency Therapeutics Inc 's Cash & cash equivalent $ 42 Millions Visit FREQ's Balance sheet
Source of FREQ's Sales Visit FREQ's Sales by Geography


Cumulative Frequency Therapeutics Inc 's Quick Ratio

FREQ's Quick Ratio for the trailling 12 Months

FREQ Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -59.08 % -50.31 % 81.05 % 83.97 % 90.78 %
Y / Y Cash & cash equivalent TTM Growth -58 % -58.13 % -43.21 % -36.42 % -32.91 %
Quick Ratio TTM 3.99 4.14 4.51 5.87 7.59
Total Ranking TTM # 605 # 625 # 655 # 608 # 495
Seq. Current Liabilities TTM Growth -1.72 % -62.21 % 4.81 % 5.11 % 19.34 %
Seq. Cash & cash equivalent TTM Growth -10.23 % -30.27 % -19.79 % -16.36 % -10.51 %


On the trailing twelve months basis In spite of the year on year decrease in FREQ's Current Liabilities to $8.19 millions, cumulative Quick Ratio to 3.99 below the FREQ average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 486 other companies have achieved higher Quick Ratio than Frequency Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 435 to 450.

Explain Quick Ratio?
How much Cash & cash equivalents FREQ´s has?
What are FREQ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 487
Healthcare Sector # 993
Within the Market # 578


trailing twelve months Quick Ratio Statistics
High Average Low
13.1 7.11 2.66
(Mar 31 2022)   (Mar 31 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Minerva Neurosciences Inc   14.00 $ 46.904  Millions$ 3.350  Millions
Rezolute Inc   13.72 $ 98.730  Millions$ 7.195  Millions
Crinetics Pharmaceuticals Inc   13.71 $ 554.653  Millions$ 40.463  Millions
Dynavax Technologies Corporation  13.28 $ 720.416  Millions$ 54.264  Millions
Kezar Life Sciences Inc   13.09 $ 218.205  Millions$ 16.672  Millions
Rocket Pharmaceuticals Inc   13.06 $ 437.171  Millions$ 33.476  Millions
Briacell Therapeutics Corp   13.04 $ 13.646  Millions$ 1.047  Millions
Vistagen Therapeutics Inc   12.93 $ 37.608  Millions$ 2.910  Millions
Rallybio Corporation  12.91 $ 121.384  Millions$ 9.402  Millions
Io Biotech Inc   12.75 $ 165.501  Millions$ 12.985  Millions
Relmada Therapeutics Inc   12.62 $ 106.267  Millions$ 8.422  Millions
Prothena Corporation Public Limited Company  12.57 $ 670.897  Millions$ 53.370  Millions
Biomea Fusion Inc   12.28 $ 199.090  Millions$ 16.210  Millions
Ligand Pharmaceuticals Incorporated  12.11 $ 190.502  Millions$ 15.727  Millions
Oric Pharmaceuticals Inc   12.00 $ 227.296  Millions$ 18.944  Millions
Anebulo Pharmaceuticals Inc   11.89 $ 8.521  Millions$ 0.717  Millions
Ovid Therapeutics Inc   11.70 $ 87.072  Millions$ 7.439  Millions
Gh Research Plc  11.70 $ 78.420  Millions$ 6.701  Millions
Sensei Biotherapeutics Inc   11.57 $ 72.013  Millions$ 6.226  Millions
Protagonist Therapeutics inc   11.51 $ 320.751  Millions$ 27.867  Millions
Ventyx Biosciences Inc   11.48 $ 300.819  Millions$ 26.208  Millions
Cormedix Inc   11.29 $ 86.587  Millions$ 7.671  Millions
Artelo Biosciences Inc   11.10 $ 10.225  Millions$ 0.921  Millions
Erasca Inc   11.10 $ 296.668  Millions$ 26.730  Millions
Anaptysbio Inc   11.03 $ 413.047  Millions$ 37.437  Millions
Mei Pharma Inc   10.95 $ 82.202  Millions$ 7.509  Millions
Ocuphire Pharma Inc   10.84 $ 42.361  Millions$ 3.909  Millions
Atai Life Sciences N v   10.77 $ 208.994  Millions$ 19.403  Millions
Nkarta Inc   10.75 $ 275.613  Millions$ 25.640  Millions
Lipocine Inc   10.64 $ 23.848  Millions$ 2.241  Millions

Date modified: 2023-11-03T16:28:11+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com